# wolverineclinic.com

# Wolverine Clinic — Independent research summaries on the BPC-157 + TB-500 blend

> Plain-English summaries of the research literature on the BPC-157 + TB-500 blend (the so-called Wolverine stack): mechanism, preclinical data, half-life, FDA and WADA status.

An independent reading room for the research literature on the BPC-157 + TB-500 blend — two mechanistically distinct research peptides, co-administered, with no controlled in-vivo combination study yet published.

## The short specification

The Wolverine blend is two research peptides — BPC-157 and TB-500 — co-administered as a tissue-repair stack. BPC-157 is a 15-amino-acid fragment of a human gastric protein; it works on the vascular side, promoting new blood-vessel formation through the VEGFR2 pathway. TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4; it works on the cytoskeletal side, binding spare actin molecules to control how cells move and rebuild. The combination rationale is that the two pathways are non-overlapping, so together they might cover more repair territory than either alone. That logic is sound on paper. What it is not is tested: no controlled study has run both peptides head-to-head against either alone. Neither compound is FDA-approved. Both are WADA-prohibited. The pages here summarize what the published literature says — and, just as plainly, what it does not. See also [what people report in practice](/effects).

## What this site is

Wolverine Clinic is a literature aggregator. It pulls together the published research on the two peptides that make up the regenerative stack sometimes called the Wolverine blend — BPC-157, a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice, and TB-500, a synthetic fragment of thymosin beta-4 carrying the LKKTETQ actin-binding motif [1][2].

Neither peptide is approved by the U.S. Food and Drug Administration for any human indication. The blend itself has no regulatory status as a combination product. In September 2023, the FDA placed both BPC-157 and TB-500 on its Category 2 list of bulk drug substances of safety concern, which effectively disqualified them from compounding under sections 503A and 503B [16]. TB-500 has been listed by the World Anti-Doping Agency under category S2 (growth factors) at all times; BPC-157 has been listed under category S0 (non-approved substances) since 2022.

This project does not sell anything. It is not a clinic. It does not employ clinicians and does not provide medical advice. The pages here summarize what the published literature actually reports, with citation numerals throughout that link to the references index.

## Two compounds, two mechanisms

The combination rationale in the preclinical literature is that the two peptides target non-overlapping pathways and might therefore complement each other in a tissue-repair context [18].

BPC-157 has been reported in rodent studies to promote angiogenesis through the VEGFR2 / Akt / endothelial nitric oxide synthase axis, to up-regulate growth hormone receptor expression in tendon fibroblasts by up to seven-fold in vitro, and to accelerate healing in models of Achilles tendon-to-bone injury, medial collateral ligament transection, gastrocnemius crush injury, and ischemic colitis [1][3][4][5][6].

TB-500 — and the full-length thymosin beta-4 from which it is derived — sequesters monomeric G-actin through the LKKTETQ motif, activates integrin-linked kinase, and accelerates cell migration in dermal, corneal, and cardiac wound models [9][10][12]. A Phase 3 ophthalmic trial of 0.1% thymosin beta-4 (RGN-259) in neurotrophic keratopathy reported complete corneal healing in 60% of treated subjects versus 12.5% on placebo at week 4 [14].

What the literature does not contain, as of this writing, is a controlled in-vivo study that directly tests the BPC-157 + TB-500 blend against either peptide alone [18]. Synergy claims in vendor copy and community forums are mechanistic extrapolations, not data.

## What the recent reviews say

A 2025 scoping review of BPC-157 for musculoskeletal healing covered 35 preclinical and one clinical study, concluding that the compound shows broad regenerative activity in animal models but that only three published human pilot studies exist (knee pain, interstitial cystitis, and intravenous safety) [16]. The reviewers noted a plasma half-life under 30 minutes, the absence of FDA approval, and classified the compound as investigational pending large-scale human trials.

A second 2025 systematic review of off-label use in orthopaedic sports medicine concluded that the clinical use of BPC-157 has outpaced the supporting human evidence and recommended formal trials before any clinical adoption [19].

For thymosin beta-4 the human evidence is more substantive — Phase 2 dermal trials in pressure ulcers, stasis ulcers, and epidermolysis bullosa, a Phase 2 dry-eye trial, and a Phase 3 ophthalmic trial — but no FDA approval has been granted for systemic indications [12][14][15].

## How to use this site

The site is organized as a technical specification sheet, not a marketing brochure.

— **/research** walks through mechanism and the most-cited preclinical studies on each component, plus the small clinical literature for thymosin beta-4. It is the densest page on the site.

— **/dosage** summarizes the dose ranges, routes, and pharmacokinetic notes reported in the published research. It explicitly does not contain a human dosing protocol.

— **/faq** answers the questions that drive most of the search traffic for the Wolverine nickname, including the regulatory and WADA questions.

— **/references** lists every cited source with DOI and PubMed link.

— **/about** describes the publisher and its editorial standards.

Every page footer carries the same disclaimer: this is research literature, not clinical advice, and nothing is for sale.

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# Wolverine blend reported effects and safety — BPC-157 + TB-500

> What the research and the research-use community report for the Wolverine blend (BPC-157 + TB-500): effects, adverse reactions, and safety cautions grounded in the published literature.

A plain account of benefits and adverse reactions — community-sourced and literature-sourced, kept strictly separate.

## The short read

The Wolverine blend — BPC-157 paired with TB-500 — is used almost exclusively for injury recovery in the research-use community. People reach for it after tendon tears, ligament sprains, post-surgical tissue damage and persistent joint problems. BPC-157 is the angiogenic side: it promotes blood-vessel formation and connective-tissue repair through the VEGFR2 pathway. TB-500 is the cytoskeletal side: the LKKTETQ motif in its sequence sequesters spare actin, a protein cells use to move and rebuild tissue.

The two mechanisms are real and independently documented — mostly in animal models, with a smaller clinical dataset for thymosin beta-4 (TB-500's parent protein) in ophthalmic and dermal trials. What the literature does not contain is a controlled study of the blend itself. No peer-reviewed study has compared both peptides together against either one alone.

Below, effects reported by the research-use community are labeled **anecdotal, not clinical evidence**. Safety cautions grounded in the literature follow, each with the relevant source.

## What people report

The following are drawn from the research-use community — peptide-user forums, athletic-recovery write-ups and wellness-context patient accounts. They are **anecdotal, not clinical evidence**: no controlled trial has measured these outcomes for the BPC-157 + TB-500 blend in people. Frequency labels reflect how commonly a given account appears, not a measured rate.

**Benefits (anecdotal, not clinical evidence)**

— *Faster recovery from tendon, ligament and muscle injuries* (very commonly reported). The main reason the community reaches for this blend. People recovering from sprains, strains, tendon tears and post-surgical injuries describe bouncing back sooner than expected. The controlled studies behind each component were done in animals on single peptides, not the blend.

— *Reduced inflammation and joint or injury pain* (very commonly reported). Reduced swelling, stiffness and pain around an injured joint or tendon over the first one to three weeks. Pain relief can also result from rest, time or expectation.

— *Improved gut comfort — attributed to the BPC-157 component* (frequently reported). Users credit BPC-157 with calmer digestion and less bloating; BPC-157 was first studied as a stomach-derived peptide. TB-500 is not associated with gut claims.

— *Better sleep and a general sense of recovery* (occasionally reported). Often tied to being in less pain rather than a direct sleep effect.

— *Mood lift or sense of wellbeing* (occasionally reported). A minority mention improved mood, sometimes linked to less pain or better gut comfort. No human study supports this for the blend.

**Adverse reactions (anecdotal, not clinical evidence)**

— *Injection-site reactions: redness, swelling, stinging, soreness* (very commonly reported). Local irritation settling within hours to a day or two — the most consistently described complaint for both components and the blend.

— *Fatigue or lethargy, especially in the first days* (frequently reported). A flat or sluggish feeling attributed mainly to the TB-500 component during an early loading period; most say it fades within the first week.

— *Head rush, lightheadedness or headache after injecting* (frequently reported). A transient rush or headache shortly after dosing, most often attributed to TB-500 at higher early doses.

— *Mild nausea, dizziness, anxiety or palpitations* (occasionally reported). A smaller share of users note these reactions, most often linked to BPC-157. Reports of mood improvement and reports of mood worsening both appear in the community — the two are inconsistent.

— *Symptoms that may come from impure or mislabeled product* (occasionally reported). Because 'Wolverine' blends are sold through unregulated channels, some reactions may come from contamination or incorrect labeling rather than the peptides themselves. Experienced users frequently flag this possibility.

## Safety and cautions

**Theoretical cancer and tumor-growth concern.** Thymosin beta-4 — the parent protein of the TB-500 component — has been linked in laboratory and tumor models to metastasis and tumor angiogenesis [20][21]. The same pro-migratory and pro-angiogenic properties that may aid healing could, in principle, support tumor progression. This is a theoretical concern grounded in preclinical data, not a documented clinical outcome.

**The blend itself has never been tested; its combined safety is unknown.** A 2025 systematic review of 36 BPC-157 studies — only one involving a human — found no clinical safety data and made no mention of TB-500 or any combination use [19]. A 2025 narrative review concluded BPC-157 should be regarded as investigational pending rigorous large-scale trials [16].

**Both components are unapproved; product identity and purity are not guaranteed.** A 2026 review of unapproved peptide therapies warns that human safety data are scarce, that there is potential for serious harm, and that these products operate largely outside regulatory oversight [22].

**WADA-prohibited; positive tests can result in sanctions.** Both ingredients are prohibited by the World Anti-Doping Agency. TB-500, as the Ac-LKKTETQ fragment of thymosin beta-4, is a confirmed doping target with validated detection methods [23][24]. BPC-157 falls under the non-approved-substances category.

**Human tolerability data are for full-length thymosin beta-4, not the TB-500 fragment.** The reassuring human IV safety studies sometimes cited in community discussion used full-length thymosin beta-4 — a 40-person Phase 1 study at doses up to 1260 mg [25] and a 2021 first-in-human study in 84 volunteers [26]. TB-500 is a 7-amino-acid fragment, a different molecule. Applying full-length protein safety data to the fragment overstates how much is actually known.

**Dual pro-angiogenic mechanism; extra caution where new vessel growth is unwanted.** BPC-157 drives angiogenesis through the VEGFR2-Akt-eNOS axis [27]; TB-500's parent protein also promotes endothelial migration and vessel formation [20]. In conditions where vessel growth is unwanted — active cancer, proliferative retinopathy — this shared mechanism is an additional consideration.

**Long-term human safety is not characterized.** No long-term human studies exist for either peptide and none for the blend. A 2025 narrative review concluded that without rigorous large-scale trials, BPC-157 should be treated as investigational [16]. Community 'loading then maintenance' protocols and fixed-ratio vials have no validated basis in controlled human trial data.

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# Research literature on the BPC-157 + TB-500 blend — Wolverine Clinic

> Mechanism and preclinical data for the BPC-157 + TB-500 (so-called Wolverine) blend: VEGFR2/Akt/eNOS angiogenesis, LKKTETQ G-actin sequestration, tendon and ligament studies, ophthalmic Phase 3 data on thymosin beta-4. Heavily cited.

Two compounds, two mechanisms, eighteen primary citations — and no controlled study of the blend itself.

## What the studies actually show

Most of the evidence for this blend is from animal studies — rats and mice with surgically damaged tendons, ligaments, muscles and blood vessels. BPC-157 has a large body of rodent work, almost all from one research group in Zagreb, showing tendon and ligament healing, vascular effects, and gut protection. TB-500 has a somewhat different problem: the most rigorous human data are on full-length thymosin beta-4, the 43-amino-acid parent protein, while TB-500 itself is a 7-amino-acid fragment. The two are related but not identical, and it matters when reading the evidence. On the human side, BPC-157 has three small pilot studies. The blend itself has none. A 2025 systematic review in the HSS Journal examined 36 BPC-157 studies, found only one human study, and reported no clinical safety data. The research page walks through the mechanism and the studies, component by component, with those caveats clearly marked.

## The combination, on paper

The Wolverine stack is a co-formulation, not a fusion peptide. BPC-157 and TB-500 are administered together — typically from research vials sold at 5 mg : 5 mg or 5 mg : 10 mg per vial by compounders — but they remain two distinct chemical entities that do not bind to each other.

The blend's published rationale, summarized in a 2025 mechanism review, is that the two peptides target non-overlapping pathways: BPC-157 supplies a vascular and connective-tissue mechanism, TB-500 supplies a cytoskeletal and re-epithelialization mechanism, and the additive effect — if any — would be greater than monotherapy [18]. That rationale is plausible. It is also unsupported by any controlled in-vivo combination study. Every published outcome in this section is from a single-agent experiment.

## BPC-157 — vascular and connective-tissue mechanism

In isolated rat aortic rings, BPC-157 at 10–100 μg/mL produced concentration-dependent vasodilation and activated the Src–Caveolin-1–endothelial nitric oxide synthase signaling pathway, releasing eNOS from its caveolin-1 anchor to roughly 50% of control values [4]. This is the most direct mechanistic evidence published for BPC-157's reported angiogenic effects.

In vitro, BPC-157 at 0.1–0.5 μg/mL up-regulated growth hormone receptor messenger RNA and protein expression in rat Achilles tendon fibroblasts by up to seven-fold by day three, with a downstream increase in fibroblast proliferation and PCNA expression upon subsequent growth-hormone exposure [5]. The mechanism — receptor up-regulation rather than direct growth-factor mimicry — is unusual in the wound-healing literature and has not been independently replicated outside the Sikiric / Chang group.

The in-vivo tendon and ligament data are consistent across more than a decade of work from a single laboratory. In rats with surgical Achilles tendon detachment, BPC-157 at 10 μg/kg intraperitoneal once daily produced substantial increases in Achilles functional index, load-to-failure, stiffness, and collagen organization, and partially offset corticosteroid-induced healing impairment [1]. A 90-day study of medial collateral ligament transection reported consistent functional, biomechanical, macroscopic, and histological improvements across intraperitoneal (10 μg/kg or 10 ng/kg), topical (1.0 μg in cream), and oral (0.16 μg/mL in drinking water) routes [2]. In a gastrocnemius crush model (force 0.727 Ns/cm²), 14 days of 10 μg/kg intraperitoneal BPC-157 reduced hematoma and edema, prevented post-injury leg contracture, and normalized creatine kinase, lactate dehydrogenase, AST, and ALT [3].

In the gastrointestinal compartment — the original indication that motivated BPC-157's clinical development — topical 10 μg/kg BPC-157 restored colonic blood supply, activated collateral circulation, and normalized malondialdehyde and nitric oxide markers in rat models of ischemic colitis [6]. Under the development name PL 14736, the compound was advanced through Phase 2 trials for inflammatory bowel disease by Pliva in Croatia; safety was reported but the program was not continued to approval [7].

A 2025 narrative scoping review covered 35 preclinical and one clinical study and concluded that BPC-157 shows broad regenerative activity in animal models but that only three published human pilot studies exist (knee pain, interstitial cystitis, and intravenous safety), with a plasma half-life under 30 minutes and no FDA approval [16]. A 2025 systematic review of off-label orthopaedic-sports-medicine use reached the same general conclusion: clinical use has outpaced the human evidence base [19].

## TB-500 and thymosin beta-4 — cytoskeletal mechanism

TB-500 as sold for research is a synthetic 7-amino-acid fragment (Ac-LKKTETQ-OH) of thymosin beta-4, a 43-amino-acid endogenous peptide. Most of the published thymosin beta-4 literature is on the 43-amino-acid parent rather than on the LKKTETQ fragment specifically — a distinction worth keeping in view when reading any TB-500 dataset.

The core mechanism is G-actin sequestration. Thymosin beta-4 binds monomeric (globular) actin so it is not available to polymerize into filaments, regulating the actin cytoskeleton dynamics that drive cell migration. In a 2004 Nature paper, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase, activated the Akt survival pathway, and — after coronary artery ligation in mice — enhanced cardiomyocyte survival and improved cardiac function [9]. A second 2007 Nature paper reported that intraperitoneal thymosin beta-4 (150 μg per dose, repeated) induced adult epicardial progenitor cell mobilization and neovascularization, restoring developmental coronary-vessel programs in adult mice [10].

In a rat embolic stroke model, thymosin beta-4 at 6 mg/kg intraperitoneal (first dose 24 hours after middle-cerebral-artery occlusion, then every three days for four doses) significantly improved functional neurological outcome on adhesive-removal and modified Neurological Severity Score tests, without reducing infarct volume — the effect was attributed to axonal remodeling, oligodendrocyte progenitor proliferation, and increased vessel density at the ischemic boundary [11].

Dermally, thymosin beta-4 has accelerated wound healing in rodent models — including aged and diabetic animals — and Phase 2 trials have reported accelerated repair in pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds [12]. At nanomolar concentrations the peptide stimulates rat vibrissa follicle clonogenic keratinocyte migration and differentiation, increases matrix metalloproteinase-2 secretion, and accelerates hair regrowth in transgenic mice that overexpress it [13].

The most rigorous human data sit in ophthalmology. A randomized, placebo-controlled, double-masked Phase 3 trial of 0.1% RGN-259 (thymosin beta-4) ophthalmic solution dosed five times daily for 4 weeks in neurotrophic keratopathy reported complete corneal healing in 60% (6 of 10) of treated subjects versus 12.5% (1 of 8) of placebo at day 29, with significant continued benefit at day 43 [14]. An earlier Phase 2 trial of 0.1% thymosin beta-4 dosed six times daily for 28 days in nine patients with severe dry eye reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal fluorescein staining at day 56, with a favorable safety profile [15].

## The combination — what is and isn't known

The honest summary: there is no controlled in-vivo combination study of the BPC-157 + TB-500 blend published in the peer-reviewed literature. The combination is plausible on mechanism — BPC-157 supplies VEGFR2/eNOS angiogenesis and gastrointestinal cytoprotection, TB-500 supplies G-actin sequestration and cell migration — and that plausibility is what motivates the stack's use in research and in unregulated practice [18].

What the published reviews emphasize, including a 2025 reply in *Pharmaceuticals* clarifying that BPC-157's angiogenic and nitric-oxide effects are highly context-dependent, is that additive benefit cannot be assumed from non-overlapping mechanisms alone [17][18]. Tissue-repair signaling is bidirectional — protective in injured tissue, but the long-term effects of chronic stimulation of angiogenesis and the actin cytoskeleton are not well characterized.

The 2025 BPC-157 musculoskeletal scoping review summarized the state of the human evidence base for BPC-157 as: three published pilot studies. For the BPC-157 + TB-500 blend specifically, that number is zero [16].

## Active research questions

Four open questions matter for any reader of this literature.

— **Is the synergy claim falsifiable?** A controlled rat tendon-repair or cardiac-repair study comparing BPC-157 alone, TB-500 alone, and the blend at matched doses would settle it. None has been published.

— **Is TB-500 (the fragment) interchangeable with thymosin beta-4 (the parent)?** Most published data are on the 43-amino-acid parent peptide. Whether the LKKTETQ fragment reproduces the full pharmacology of the parent in vivo is not fully established.

— **Is the BPC-157 mechanism literature externally valid?** The large majority of the rodent literature comes from a single research group in Zagreb. Independent replication outside that group is comparatively sparse [16][17].

— **What are the long-term safety implications of chronic angiogenic and actin-cytoskeletal stimulation?** Theoretical concerns include pathologic (non-physiologic) angiogenesis, immunogenicity from peptide impurities in compounded products, and unknown effects on tissues with high resident progenitor populations. These have not been characterized in adequately powered human studies.

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# Research-context dosing for the BPC-157 + TB-500 blend — Wolverine Clinic

> Dose ranges, routes, and pharmacokinetic notes from the BPC-157 and TB-500 research literature. No FDA-approved human dose exists for either peptide or for the blend. Research context only.

Rodent intraperitoneal microgram-per-kilogram regimens and topical ophthalmic concentrations — not human dosing protocols.

## Doses from the published studies — not a protocol

There is no FDA-approved dose for BPC-157, no approved dose for TB-500, and no validated dose for the blend as a combination. What the dosage page contains is what the published studies used, in the species and models in which they used it. For BPC-157, the most common rodent regimen is 10 micrograms per kilogram, intraperitoneal, once daily. For thymosin beta-4, human IV trials have used milligrams-per-kilogram ranges that bear no direct relationship to community protocols for the fragment. BPC-157's plasma half-life in animal studies is under 30 minutes. No pharmacokinetic data exist for the TB-500 fragment specifically at research doses. The dosage page reports these figures in their research context. It does not contain a human dosing protocol, because none exists in the controlled literature.

## Regulatory baseline

There is no FDA-approved human dose for BPC-157, no FDA-approved human dose for TB-500, and no regulatory status whatsoever for the BPC-157 + TB-500 blend as a combination product. In September 2023, the FDA placed both BPC-157 and TB-500 on its Category 2 list of bulk drug substances of safety concern, effectively disqualifying them from compounding under sections 503A and 503B of the Food, Drug, and Cosmetic Act [16].

TB-500 (and any thymosin beta-4 derivative) is prohibited at all times by the World Anti-Doping Agency under category S2 (growth factors). BPC-157 has been listed by WADA under category S0 (non-approved substances) since 2022. A Canadian athlete received a four-year sanction for TB-500 use [16].

What follows is a summary of the dose ranges and routes documented in the published preclinical and clinical literature, reported in research context. It is not a recommendation.

## BPC-157 — what doses the research used

The most commonly tested rodent intraperitoneal regimen for BPC-157 across the Sikiric-lab tendon, ligament, muscle, and gastrointestinal studies is **10 μg/kg once daily**, with parallel arms at 10 ng/kg and occasionally 10 pg/kg to confirm dose responsiveness [1][3]. The Achilles detachment study used this dose to produce functional and biomechanical improvements that did not occur spontaneously in controls [1]. The gastrocnemius crush study used the same intraperitoneal regimen for 14 days [3].

Two other routes have been reported in rodent connective-tissue work:

— **Topical** — 1.0 μg dissolved per gram of neutral cream, applied to the injury site [2].

— **Oral / drinking water** — approximately 0.16 μg/mL in drinking water, eaten ad libitum [2]. BPC-157's reported stability in human gastric juice is what underlies the use of oral administration in preclinical work; whether the same oral bioavailability translates to human pharmacokinetics has not been established.

The 2025 scoping review covered 35 preclinical studies and concluded that the rodent dose range and intraperitoneal route are the dominant pattern in the published BPC-157 literature, with only three small human pilot studies on record [16].

## TB-500 and thymosin beta-4 — what doses the research used

TB-500 dosing in published research is more heterogeneous than BPC-157 dosing, because most of the data are on full-length thymosin beta-4 rather than the LKKTETQ fragment specifically.

In the rat embolic stroke model, thymosin beta-4 was administered at **6 mg/kg intraperitoneal**, first 24 hours after middle-cerebral-artery occlusion and then every three days for four doses [11]. In the mouse cardiac repair models, doses of **150 μg per mouse (intraperitoneal)** were used for adult epicardial progenitor mobilization and neovascularization, with intracardiac and systemic delivery both reported [10]. The 2004 *Nature* paper describing PINCH / ILK complex formation and Akt activation did not specify a single dose in its abstract; the experimental paper reported both intracardiac and intraperitoneal delivery [9].

The human ophthalmic trials of thymosin beta-4 used **0.1% topical solution (RGN-259)**, dosed five times daily for four weeks (Phase 3 neurotrophic keratopathy) [14] or six times daily for 28 days (Phase 2 severe dry eye) [15]. The dermal Phase 2 work in pressure ulcers, stasis ulcers, and epidermolysis bullosa used topical formulations in trial; preclinical work has used both topical and subcutaneous routes [12].

No published controlled trial has established a human systemic dose for TB-500 or thymosin beta-4. Vendor-published 'protocols' for the synthetic fragment are not derived from controlled human pharmacokinetic data.

## Pharmacokinetics and route considerations

BPC-157's plasma half-life in preclinical work is reported as **under 30 minutes**, with hepatic metabolism and renal clearance [16]. Thymosin beta-4 is also short-lived in circulation. The 2025 scoping review identified this short half-life as a key limitation for translational dosing — repeated administration is required to maintain any plasma exposure, and the relevance of brief systemic peaks to the regenerative effects seen in tissue is not fully resolved.

The routes most commonly reported in the published research are intraperitoneal (most rodent studies for both peptides), subcutaneous (vendor-typical research protocols), topical (BPC-157 wound and joint studies; thymosin beta-4 ophthalmic and dermal trials), oral via drinking water (BPC-157 only, rodent), and intracardiac (thymosin beta-4 cardiac models). Whether the local-tissue concentrations achieved in any of these routes translate to a human therapeutic window is not established for either peptide.

BPC-157 is described in the literature as stable in human gastric juice, which is the basis for oral preclinical dosing. TB-500 and thymosin beta-4 are conventionally formulated for parenteral administration; oral bioavailability of the LKKTETQ fragment is not well characterized.

## The blend itself

Compounders sell research vials of the BPC-157 + TB-500 blend in two common ratios — **5 mg : 5 mg** and **5 mg : 10 mg per vial** — but there is no consensus dose because there is no FDA-approved combination product and no controlled in-vivo combination study published in the peer-reviewed literature [18]. Any 'protocol' circulating in forum threads or vendor copy for the blend specifically is an extrapolation from the single-agent rodent literature, not a dose validated against the combination.

The most defensible thing to say about the blend's dosing is that the published evidence supports each individual peptide at the doses and routes described above, in the species and models in which it has been studied. The published evidence does not support any specific human regimen for either compound, alone or together.

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# FAQ — BPC-157 + TB-500 blend research — Wolverine Clinic

> Common questions about the BPC-157 + TB-500 (so-called Wolverine) blend: what it is, what the research shows, FDA and WADA status, why no synergy data exists, and what the Wolverine nickname means.

Direct answers to the questions that drive most of the search traffic for this stack.

## What is the Wolverine peptide blend?

The Wolverine blend is a co-formulation of two research peptides — BPC-157, a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice, and TB-500, a synthetic 7-amino-acid fragment of thymosin beta-4 carrying the LKKTETQ actin-binding motif. The two peptides are administered together but do not form a single chemical complex; the blend is a co-formulation, not a fusion peptide. The nickname comes from the research community, referring to the perceived regenerative character of the combination. Neither compound is FDA-approved for any human indication, and the blend itself has no regulatory status as a combination product [16][18].

## Why is it called the Wolverine stack?

The name is a community nickname for the perceived rapid-healing character of combining a peptide associated with angiogenesis and connective-tissue repair (BPC-157) with one associated with cell migration and re-epithelialization (TB-500). The label is descriptive shorthand, not a brand. Wolverine Clinic is an independent editorial project; it is not affiliated with Marvel Entertainment, the comic-book or film franchise, or any related trademark holder. Throughout this site the literal compound names are used in preference to the nickname wherever clarity permits.

## What does the research say about combining BPC-157 and TB-500?

No controlled in-vivo study has directly compared the BPC-157 + TB-500 blend against either peptide administered alone. The combination rationale published in mechanism reviews is that the two peptides target non-overlapping pathways — BPC-157 supplies a VEGFR2 / Akt / eNOS angiogenesis and gastrointestinal cytoprotection mechanism, TB-500 supplies G-actin sequestration and cell migration via the LKKTETQ motif and integrin-linked kinase — and additive benefit is therefore plausible. Plausibility is not data. Every published outcome in either component's literature is from a single-agent experiment [4][5][9][10][18].

## Is the Wolverine blend FDA-approved?

No. Neither BPC-157 nor TB-500 is approved by the U.S. Food and Drug Administration for any human indication, and the blend has no regulatory status as a combination product. In September 2023, the FDA placed both compounds on its Category 2 list of bulk drug substances of safety concern, which effectively prohibits 503A and 503B compounding pharmacies from producing them. The regulatory landscape has continued to evolve and the current status should be checked against the FDA's published lists [16].

## Is TB-500 banned by WADA?

Yes. The World Anti-Doping Agency explicitly prohibits thymosin beta-4 and its derivatives — which includes TB-500 — at all times under category S2 (growth factors and growth-factor modulators). BPC-157 is also listed by WADA, under category S0 (non-approved substances), with effect from 2022. A Canadian athlete received a four-year sanction for TB-500 use. Any athlete subject to WADA testing should treat the Wolverine blend as prohibited [16].

## Is TB-500 the same as thymosin beta-4?

Not exactly. TB-500, as sold for research, is a synthetic 7-amino-acid fragment (Ac-LKKTETQ-OH) of thymosin beta-4, a 43-amino-acid endogenous peptide. The LKKTETQ motif is the actin-binding domain of the parent peptide, and most of the published mechanistic data — the PINCH/ILK complex formation, the cardiac repair work, the dermal wound studies, the ophthalmic trials — are on the 43-amino-acid parent rather than on the fragment specifically. Whether the fragment fully reproduces the parent peptide's pharmacology in vivo is not completely established [9][10][12][14].

## How does BPC-157 work mechanistically?

Two main mechanisms are reported. First, BPC-157 promotes angiogenesis through activation of the Src–Caveolin-1–endothelial nitric oxide synthase (eNOS) pathway in vascular endothelium, with downstream effects on VEGFR2 signaling. In isolated rat aortic rings at 10–100 μg/mL, BPC-157 produced concentration-dependent vasodilation and released eNOS from caveolin-1 binding to roughly 50% of control [4]. Second, in vitro at 0.1–0.5 μg/mL it up-regulates growth hormone receptor expression in rat Achilles tendon fibroblasts by up to seven-fold by day three, sensitizing the cells to subsequent growth-hormone exposure [5]. These mechanisms are reported alongside down-regulation of NF-kB and pro-inflammatory cytokines TNF-alpha, IL-6, and IL-1beta in injured-tissue models.

## How does TB-500 (thymosin beta-4 fragment) work mechanistically?

The core mechanism is G-actin sequestration. Thymosin beta-4 — and its LKKTETQ fragment — binds monomeric (globular) actin so it is not available to polymerize into filaments, regulating the actin cytoskeleton dynamics that drive cell migration. Downstream, the peptide activates integrin-linked kinase, forms a functional complex with PINCH, and stimulates the Akt survival pathway. In the cardiac literature, this mechanism translated into enhanced cardiomyocyte survival and improved cardiac function after coronary artery ligation in mice [9]. In the dermal literature, the same cytoskeletal mechanism is implicated in accelerated wound closure and re-epithelialization across rodent models and Phase 2 trials [12].

## Has any study directly compared the blend against either peptide alone?

No. The 2025 mechanism reviews of BPC-157 and the published commentary on the BPC-157 + TB-500 combination both note that additive effects are plausible on mechanism, because the pathways are non-overlapping, but that no controlled in-vivo study has directly compared the blend against monotherapy. The 2025 BPC-157 scoping review reported three published human pilot studies of BPC-157 alone; for the BPC-157 + TB-500 blend specifically, the count is zero [16][18].

## What research doses have been used for BPC-157 and TB-500 in animal studies?

BPC-157 in rodent models was most commonly studied at 10 μg/kg intraperitoneal once daily across the Sikiric-lab tendon, ligament, muscle, and gastrointestinal work, with parallel arms at 10 ng/kg and occasionally 10 pg/kg [1][3]. Topical use in rodents was at 1 μg dissolved per gram of neutral cream; oral use was at approximately 0.16 μg/mL in drinking water [2]. TB-500 / thymosin beta-4 in the rat stroke model was administered at 6 mg/kg intraperitoneal, first 24 hours after middle-cerebral-artery occlusion then every three days for four doses [11]; in mouse cardiac models, 150 μg per mouse intraperitoneal was used [10]. Human ophthalmic trials of thymosin beta-4 used 0.1% topical solution dosed five to six times daily for several weeks [14][15].

## What is the half-life of BPC-157?

BPC-157's plasma half-life in preclinical work is reported as under 30 minutes, with hepatic metabolism and renal clearance. Thymosin beta-4 is also short-lived in circulation. The 2025 scoping review of BPC-157 in musculoskeletal healing cited this short half-life as a key limitation for translational dosing — repeated administration is required to maintain any plasma exposure, and how brief systemic peaks translate to the tissue-level regenerative effects in animal models is not fully resolved [16].

## Is the Wolverine stack safe in research models?

The preclinical safety profile of both peptides in animal studies has been characterized as favorable in the published reviews, including the 2025 literature and patent review and the 2025 musculoskeletal scoping review [16][17]. That preclinical signal does not establish human safety. Theoretical concerns for chronic dosing include pathologic (non-physiologic) angiogenesis, immunogenicity from peptide impurities in compounded products, and unknown long-term effects on tissues with high resident progenitor populations. None of these has been characterized in adequately powered human studies of either peptide, let alone the blend.

## Does the site sell the Wolverine blend?

No. Wolverine Clinic is an independent editorial project that summarizes the research literature on the BPC-157 + TB-500 blend. It does not sell, manufacture, distribute, broker, or refer for any product. It is not affiliated with any vendor or compounding pharmacy. The site does not link to vendors, does not run affiliate offers, and does not collect orders. All citations point to primary research sources — PubMed, PubMed Central, peer-reviewed journals — not commercial vendors.

## Is Wolverine Clinic a real clinic?

No. Despite the 'clinic' in the domain name, Wolverine Clinic is not a medical clinic and does not provide clinical services. It does not employ clinicians and does not offer consultation, prescription, diagnosis, or treatment. The 'clinic' modifier here is editorial framing — a position the publisher occupies relative to the published research literature, not a claim about clinical services. The /about page describes the editorial standards and entity behind the site in more detail.

## Where does the BPC-157 research literature come from?

The large majority of the BPC-157 preclinical literature originates from the laboratory of Predrag Sikiric and Sven Seiwerth in Zagreb, Croatia, who first described the peptide in the 1990s. The same group developed the compound under the names PL-10, PLD-116, and PL 14736, and advanced it through Phase 2 trials for inflammatory bowel disease under Pliva (Croatia) before the program was discontinued without proceeding to approval [7]. Independent replication of the major preclinical findings outside the Sikiric group is comparatively sparse — a point flagged by the 2025 scoping review as a limitation of the evidence base [16].

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# References — BPC-157 + TB-500 blend research — Wolverine Clinic

> Full citation list for the BPC-157 + TB-500 (Wolverine) blend research summary: PubMed and PubMed Central links, DOIs, journal references for every claim on the site.

DOI and PubMed link for each citation. Numbered to match the inline markers throughout the site.

## How this list is built

Every numeric citation marker in the body of this site — `[1]`, `[2]`, and so on — corresponds to one of the entries below. The list is sorted in citation order, not alphabetically. Each entry carries the title, authors, journal, year, DOI, PubMed identifier where available, and a direct link to the open-source full text or the PubMed listing.

The references are split between two compound bodies: the BPC-157 preclinical and review literature (entries 1–8 and 16–17, 19), and the thymosin beta-4 / TB-500 preclinical and clinical literature (entries 9–15). Entry 18 is the published mechanism commentary on the BPC-157 + TB-500 combination specifically.

All entries link to publicly accessible records on PubMed, PubMed Central, or the open-access publisher page. None of the links are to commercial vendor sites; none of the sources cited is a vendor publication.

## Notes on the evidence base

Several characteristics of the underlying literature are worth noting before reading the list:

— The BPC-157 preclinical record is dominated by work from a single research group (Sikiric / Seiwerth in Zagreb). Independent replication outside that group is comparatively sparse.

— Most of the thymosin beta-4 mechanism and outcome data are on the full-length 43-amino-acid parent peptide, not on the 7-amino-acid LKKTETQ fragment (TB-500) sold for research.

— Human clinical data for BPC-157 are limited to three published pilot studies; for thymosin beta-4 they include Phase 2 dermal trials, a Phase 2 dry-eye trial, and a Phase 3 ophthalmic trial in neurotrophic keratopathy.

— No controlled in-vivo study of the BPC-157 + TB-500 blend versus either monotherapy has been published.

The full citation list follows in the assembler's rendering of `references_index` below.

## References

[1] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006. https://pubmed.ncbi.nlm.nih.gov/16583442/
[2] Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010. https://pubmed.ncbi.nlm.nih.gov/20225319/
[3] Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery Today. 2008. https://pubmed.ncbi.nlm.nih.gov/18668315/
[4] Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/
[5] Chang CH, Tsai WC, Hsu YH, Pang JS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
[6] Duzel A, Vlainic J, Antunovic M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World Journal of Gastroenterology. 2017;23(48):8465. https://pubmed.ncbi.nlm.nih.gov/29358856/
[7] Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006. https://pubmed.ncbi.nlm.nih.gov/17186181/
[8] Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC 157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sciences. 2004. https://pubmed.ncbi.nlm.nih.gov/15531385/
[9] Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. https://pubmed.ncbi.nlm.nih.gov/15565145/
[10] Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007. https://pubmed.ncbi.nlm.nih.gov/17108969/
[11] Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2907184/
[12] Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development. 2004. https://pubmed.ncbi.nlm.nih.gov/15037013/
[13] Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, Orgel A, Kleinman HK, Elkin M. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB Journal. 2004. https://pubmed.ncbi.nlm.nih.gov/14657002/
[14] Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. International Journal of Molecular Sciences. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
[15] Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a Phase 2 randomized trial. Cornea. 2015. https://pubmed.ncbi.nlm.nih.gov/25826322/
[16] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
[17] Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025. https://www.mdpi.com/1424-8247/18/2/185
[18] Jozwiak M, Bauer M, Kamysz W, Kleczkowska P (reply); Sikiric P et al. (comment). Reply to Sikiric et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Comment on Jozwiak et al. Pharmaceuticals. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12567171/
[19] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://doi.org/10.1177/15563316251355551
[20] Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute. 2003. https://pubmed.ncbi.nlm.nih.gov/14625258/
[21] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[22] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[23] Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012. https://pubmed.ncbi.nlm.nih.gov/23084823/
[24] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[25] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
[26] et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/34346165/
[27] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017. https://pubmed.ncbi.nlm.nih.gov/27847966/

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# About Wolverine Clinic — Independent editorial project on the BPC-157 + TB-500 blend

> Wolverine Clinic is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 + TB-500 blend. Not a clinic. Not a vendor. No medical advice.

What the publisher is, what it isn't, and how it sources the material on this site.

## What Wolverine Clinic is

Wolverine Clinic is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 + TB-500 blend (the so-called Wolverine stack) and its two components. The site exists to give readers — human and machine — a single, citation-dense place to read the published research on this combination without the noise that surrounds it in vendor copy, forum threads, and social media.

The publisher is not a clinic. It does not employ clinicians and does not provide medical advice. It does not manufacture, sell, distribute, broker, or refer for any product. Its work is editorial commentary on publicly available science. Every quantitative claim on the site is sourced to a primary research paper, listed in the references index with DOI and PubMed link.

The word 'clinic' in the domain name is editorial framing — a position the publisher occupies relative to the literature, in the sense of a research-literature clinic or technical reading room. It is not a claim that the site provides clinical services, runs a medical practice, or treats patients.

## What it isn't

Specifically, Wolverine Clinic is not:

— a medical clinic, hospital, or practice;

— a pharmacy, compounding pharmacy, or distributor;

— a vendor of BPC-157, TB-500, the Wolverine blend, or any other research compound;

— a telehealth or prescription service;

— a substitute for a qualified medical professional;

— affiliated with Marvel Entertainment, the *Wolverine* / X-Men franchise, or any related trademark holder. The nickname 'Wolverine' for the BPC-157 + TB-500 blend is a community label used in research and discussion forums; it is used here in that descriptive sense only.

Nothing on this site is medical advice. Nothing on this site is an offer to sell anything.

## Editorial standards and sourcing

Every claim on the site is tied to a citation in the references index. The sources are weighted in this order of preference: peer-reviewed primary research articles (PubMed-indexed), peer-reviewed systematic reviews and scoping reviews, official regulatory documents (FDA, WADA), and authoritative reference works.

When the published evidence is sparse — as it is, for example, for the BPC-157 + TB-500 combination specifically — the site says so. When the evidence is strong in one model but unreplicated in another, the site says that too. The voice across the site is meant to be the engineering-drawing register implied by the design: specific, sourced, restrained.

The site does not write opinion. It does not write recommendations. It does not endorse vendors or products. It does not promote off-label or unapproved use of any compound. Where the published research literature contains gaps, uncertainties, or active disputes, the site reports them as such rather than papering over them.

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.

---

# Contact — Wolverine Clinic

> Contact the editor at Wolverine Clinic — independent editorial project on the BPC-157 + TB-500 blend research literature. Editorial corrections and citation suggestions welcome.

One channel, one editor. No medical advice, no product orders, no clinical consultation.

## Get in touch

The fastest way to reach the editor is the form below. It is monitored for editorial correspondence — corrections to citations on this site, pointers to newly published peer-reviewed work on BPC-157, TB-500, or the combination, and structural feedback on the literature summaries. The site uses any corrections it receives to update the public pages.

The form does not collect orders, requests for prescriptions, requests for consultation, or requests for medical advice. The publisher cannot and will not respond to any of those. The site is an editorial project on research literature; it is not a clinic, a pharmacy, or a vendor.

If the question is about an individual medical or research decision, please consult a qualified professional or, for clinical questions, your physician. The reference list on this site links to the original primary sources, which are themselves the best starting point for a substantive technical question.

## What the form is for

Appropriate uses of the contact form include:

— pointing out a factual error or broken citation on any page of the site;

— suggesting a published peer-reviewed paper that should be cited in the next editorial update;

— flagging a regulatory update (for example, a change in FDA or WADA status that has been published since the last edit);

— offering structural or editorial feedback on the literature summaries.

Inappropriate uses include any of the categories listed in the section above (orders, prescriptions, medical consultation, etc.). Messages of that kind will not receive a response.

---

Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.